Lördag 10 Maj | 04:46:21 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2025-10-30 07:30 Kvartalsrapport 2025-Q3
2025-07-10 07:30 Kvartalsrapport 2025-Q2
2025-06-26 N/A Årsstämma
2025-05-23 N/A X-dag ordinarie utdelning QLINEA 0.00 SEK
2025-04-14 - Kvartalsrapport 2025-Q1
2025-04-03 - Extra Bolagsstämma 2025
2025-02-28 - Bokslutskommuniké 2024
2024-11-05 - Kvartalsrapport 2024-Q3
2024-07-11 - Kvartalsrapport 2024-Q2
2024-06-28 - Årsstämma
2024-06-12 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2024-05-31 - Kvartalsrapport 2024-Q1
2024-02-27 - Bokslutskommuniké 2023
2023-11-02 - Kvartalsrapport 2023-Q3
2023-07-13 - Kvartalsrapport 2023-Q2
2023-07-03 - Extra Bolagsstämma 2023
2023-06-13 - Årsstämma
2023-05-24 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2023-05-04 - Kvartalsrapport 2023-Q1
2023-02-16 - Bokslutskommuniké 2022
2022-11-03 - Kvartalsrapport 2022-Q3
2022-07-14 - Kvartalsrapport 2022-Q2
2022-05-25 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2022-05-24 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-04 - Kvartalsrapport 2021-Q3
2021-07-15 - Kvartalsrapport 2021-Q2
2021-05-26 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2021-05-25 - Årsstämma
2021-05-06 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-07-16 - Kvartalsrapport 2020-Q2
2020-05-27 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2020-05-26 - Årsstämma
2020-05-07 - Kvartalsrapport 2020-Q1
2020-02-13 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-07-18 - Kvartalsrapport 2019-Q2
2019-05-23 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2019-05-22 - Årsstämma
2019-05-03 - Kvartalsrapport 2019-Q1
2019-02-14 - Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Q-Linea är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av instrument och förbrukningsartiklar. Produkterna används huvudsakligen vid behandling av infektionssjukdomar och blodförgiftning, och innefattar diagnostik- och analysverktyg, samt grundläggande provhantering. Tekniken baseras på den så kallade ID- samt AST tekniken. Q-Linea grundades 2008 och har huvudkontor i Uppsala.
2025-03-27 08:35:00

Q-linea AB (publ) ("Q-linea" or the "Company") (Nasdaq Stockholm: QLINEA), has received information from the Company's shareholder Nexttobe AB ("Nexttobe") that they have completed a sale of all held warrants of series TO 1 ("warrants") to Investment AB Öresund ("Öresund"), which has undertaken, under certain conditions, to utilize these warrants for subscription of new ordinary shares.

Stuart Gander, CEO in Q-linea, comments:

“We are very glad that Öresund has shown a strong interest to increase their shareholding and engagement in Q-linea. Doing this through the warrants is also beneficial for Q-linea, as it will increase the likelihood of a successful warrant programme in May 2025 and directly support the Company’s capital needs.”

On 5 November 2024, Q-linea announced that the board of directors had resolved on a rights issue of up to approximately SEK 225 million, which subsequently was approved by the extraordinary general meeting on 6 December 2024. Four (4) unit rights entitled the holder to subscribe for one (1) Unit, where each Unit consists of two (2) ordinary shares and one (1) warrant of series TO1 free of charge.

Each warrant of series TO1 entitles the holder to subscribe for one (1) new ordinary share in Q-linea during the period from 5 May 2025 up to and including 19 May 2025. The exercise price for the warrants corresponds to 70 percent of the volume-weighted average price of the Company’s share on Nasdaq Stockholm during the period from 14 April 2025 up to and including 29 April 2025, however not lower than the share’s quota value.

Q-linea's operations may, upon assessment, be considered to conduct protected activities according to the Act (2023:560) on the Review of Foreign Direct Investments. Consequently, an investment in shares through the exercise of the warrants that results in an investor acquiring a shareholding equivalent to or exceeding certain thresholds of the total number of votes in the Company after the exercise of the warrants must be reported to the Inspectorate for Strategic Products ("ISP") before the investment can be carried out. The investment may not be executed until the Inspectorate for Strategic Products has either taken no action on the notification or approved the investment.

Q-linea has received information from the Company's shareholder Nexttobe AB that they have completed a sale of all warrants held, corresponding to 500,000,000 warrants, to Öresund. In connection with the acquisition, Öresund has undertaken to exercise all acquired warrants provided that Öresund receives approval from ISP and that the warrants are so-called "in-the-money", i.e. that the subscription price is below the current share price, during the entire exercise period, from 5 May 2025 up to and including 19 May 2025.